false
English
Catalog
2024 World Conference on Lung Cancer (WCLC) - Post ...
P1.12A.07 A Phase 1 Study of TY-9591 in Advanced N ...
P1.12A.07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation.
Back to course
Pdf Summary
This document presents a Phase 1 study of TY-9591, a third-generation EGFR tyrosine kinase inhibitor (TKI), in patients with advanced non-small cell lung cancer (NSCLC) with EGFR mutations. The motivation for the study stems from the insufficient efficacy of current third-generation TKIs, especially in cases with brain metastases or L858R mutations. TY-9591 aims to address these gaps, showcasing potential for improved efficacy and decreased side effects by reducing the exposure to toxic metabolites compared to similar treatments like osimertinib.<br /><br />The study encompassed a first-in-human, dose escalation and expansion approach, involving 105 patients with advanced or metastatic EGFR mutation-positive NSCLC who have progressed on prior treatments. The primary goal was to assess safety and efficacy, with secondary endpoints including overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).<br /><br />Results indicate that TY-9591 is safe and well-tolerated, with no significant safety issues like interstitial lung disease or cardiomyopathy, though QTc interval prolongation was noted. It demonstrated high efficacy, particularly for L858R mutations and brain metastases, observing a higher ORR and DCR at a 160 mg dose compared to 80 mg and 120 mg. The intracranial ORR in patients with measurable brain lesions was 90.9%, predominantly seen in the 160 mg group.<br /><br />Early findings suggest promising outcomes with TY-9591, sparking ongoing comparative studies against osimertinib in Phase 2 and Phase 3 trials. These aim to further verify TY-9591's superiority in treating NSCLC patients with challenging mutations or brain metastases. Overall, this study highlights TY-9591 as a potential advanced treatment option, warranting further research into its long-term benefits and optimal dosing.
Asset Subtitle
Baohui Han
Meta Tag
Speaker
Baohui Han
Topic
Metastatic NSCLC – Targeted Therapy
Keywords
TY-9591
EGFR mutations
non-small cell lung cancer
third-generation TKI
brain metastases
L858R mutations
dose escalation
safety and efficacy
progression-free survival
osimertinib
×
Please select your language
1
English
5
普通话
11
Dutch